Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277498 · ClinicalTrials.gov registry record · Phase 3
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 528
- Enrollment target
- 20
- Study locations
NCT00277498: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00277498 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 528 participants, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00277498, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 528 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Conditions Studied
Interventions
- DRUG Timolol
- DRUG Xalacom
- DRUG Xalatan
Study Locations (20)
California
- Pfizer Investigational Site - Artesia
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Newport Beach
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - San Francisco
Florida
- Pfizer Investigational Site - Gainesville
- Pfizer Investigational Site - Lecanto
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Panama City
Illinois
- Pfizer Investigational Site - Bourbonnais
- Pfizer Investigational Site - Calumet City
- Pfizer Investigational Site - Chicago
- Pfizer Investigational Site - Chicago
Indiana
- Pfizer Investigational Site - Evansville
- Pfizer Investigational Site - Madison
- Pfizer Investigational Site - New Albany
Alabama
- Pfizer Investigational Site - Birmingham
Arizona
- Pfizer Investigational Site - Flagstaff
Colorado
- Pfizer Investigational Site - Colorado Springs
Idaho
- Pfizer Investigational Site - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
What the finished NCT00277498 record still lists
NCT00277498 is an interventional study that assigns participants to a tested intervention. The registered 528 participants enrollment target is mid-sized for trials with a published cap, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (97% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Timolol is the first listed.
NCT00277498 names 20 study sites across 8 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00277498 about?
NCT00277498 is a clinical study titled "A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma". To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
What is the current status of trial NCT00277498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 528 participants. The study started on 2005-12. Estimated completion is 2007-06.
What conditions does trial NCT00277498 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT00277498?
The interventions under investigation include: Timolol (DRUG), Xalacom (DRUG), Xalatan (DRUG).
Who is sponsoring clinical trial NCT00277498?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00277498 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00277498's enrollment target sits among peer trials
528 11th of 54 higher than 44 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia